1. Home
  2. UGI vs TGTX Comparison

UGI vs TGTX Comparison

Compare UGI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UGI Corporation

UGI

UGI Corporation

HOLD

Current Price

$36.38

Market Cap

7.2B

Sector

Utilities

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.99

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UGI
TGTX
Founded
1940
1993
Country
United States
United States
Employees
9400
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
8.5B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
UGI
TGTX
Price
$36.38
$53.99
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$44.00
$49.80
AVG Volume (30 Days)
1.3M
2.5M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
3.99%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
$8.88
$49.08
Revenue Next Year
$2.27
$26.69
P/E Ratio
$14.04
$449.67
Revenue Growth
N/A
N/A
52 Week Low
$31.62
$25.37
52 Week High
$41.34
$59.30

Technical Indicators

Market Signals
Indicator
UGI
TGTX
Relative Strength Index (RSI) 59.09 54.75
Support Level $35.66 $51.15
Resistance Level $37.58 $58.34
Average True Range (ATR) 0.68 2.44
MACD 0.12 -0.80
Stochastic Oscillator 64.93 37.18

Price Performance

Historical Comparison
UGI
TGTX

About UGI UGI Corporation

UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: